25 years experience in life science advisory, investment and portfolio management. Served as Venture Partner of Global Biomedical Partners (GBP), managing $100 million BIOMEDICINE fund. Former member of Board of Directors of Innodia Inc and observer on board of Syntonix Pharmaceuticals. Has advised hundreds of companies, investment firms, universities and government agencies worldwide, frequent speaker at biotechnology investment conferences in US, Europe and Asia, served as a reviewer to the US Congressional Office of Technology Assessment in its first report on commercial biotechnology in 1983. Previously associated with Adler & Co., Euclid Partners and the corporate venture arm of WR Grace & Co. A.B., Biochemistry from Harvard University, conducted research in tumor immunology at Dana Farber Cancer Center and Yale University.